Yigit Hande, Ulusoy Emel, Guneysu Songul Tomar, Colak Ozlem, Gultekingil Ayse, Guleryuz Oksan Derinoz, Yilmaz Durgul, Duman Murat, Teksam Ozlem
Faculty of Medicine, Department of Pediatrics, Division of Pediatric Emergency Medicine, Hacettepe University, Ankara, Türkiye, Turkey.
Faculty of Medicine, Department of Pediatrics, Division of Pediatric Emergency Medicine, Dokuz Eylul University, İzmir, Türkiye, Turkey.
BMC Infect Dis. 2024 Dec 18;24(1):1444. doi: 10.1186/s12879-024-10356-6.
The primary aim of this study was to compare the groups, SARS-CoV-2-positive and -negative patients, in terms of the frequency of SBI. The SARS-CoV-2-positive group was compared with the other-RVPs-positive group as a secondary evaluation in terms of serious bacterial infection (SBI).
This retrospective multicenter cohort study was conducted at four university hospitals from March 2020 to December 2021. Patients under 90 days old, with a measured fever of ≥ 38 °C, who were tested for SARS-CoV-2 and had blood and urine cultures taken, were included in the study. The patient groups who tested positive and negative for SARS-CoV-2 were compared regarding clinical characteristics, laboratory data, and the frequency of serious bacterial infections. As a secondary analysis, among patients tested for other respiratory viruses, the SARS-CoV-2-positive group and other respiratory virus-positive groups were compared in terms of the frequency of SBI.
A total of 208 patients met the inclusion criteria. Two distinct comparisons were conducted among the patients included in the study: the first between the SARS-CoV-2-positive and SARS-CoV-2-negative patient groups, and the second between the SARS-CoV-2-positive and other RVPs-positive patient groups. In the first comparison, fifty-five patients were SARS-CoV-2-positive and 153 were SARS-CoV-2-negative. The rate of SBI in the SARS-CoV-2-positive patients was 16.4%, whereas that in the SARS-CoV-2-negative patients was 47.1%. The laboratory parameters for infection suspicion were significantly lower in the SARS-CoV-2-positive group than the SARS-CoV-2-negative group. In the second comparison, 90 patients who were tested for both SARS-CoV-2 and other RVPs were evaluated. The mean WBC, ANC and CRP levels were significantly lower in the SARS-CoV-2-positive group than the other RVPs-positive group, however, there was no significant difference in the mean ALC, NLR and PCT levels and the frequency of SBI between the SARS-CoV-2-positive and other RVPs-positive patient groups.
These results suggest that febrile infants younger than 90 days with SARS-CoV-2 have lower rates of SBI than patients without SARS-CoV-2. These data are consistent with previous studies describing lower risks of SBI in febrile infants with RVPs.
Not applicable.
本研究的主要目的是比较新型冠状病毒2（SARS-CoV-2）阳性和阴性患者的严重细菌感染（SBI）发生率。作为对严重细菌感染的次要评估，将SARS-CoV-2阳性组与其他呼吸道病毒阳性组进行比较。
本回顾性多中心队列研究于2020年3月至2021年12月在四家大学医院进行。纳入研究的患者为90日龄以下、测量体温≥38°C、接受过SARS-CoV-2检测并进行了血培养和尿培养的患者。比较SARS-CoV-2检测呈阳性和阴性的患者组的临床特征、实验室数据以及严重细菌感染的发生率。作为次要分析，在检测了其他呼吸道病毒的患者中，比较SARS-CoV-2阳性组和其他呼吸道病毒阳性组的SBI发生率。
共有208例患者符合纳入标准。在纳入研究的患者中进行了两项不同的比较：第一项是SARS-CoV-2阳性和阴性患者组之间的比较，第二项是SARS-CoV-2阳性和其他呼吸道病毒阳性患者组之间的比较。在第一项比较中，55例患者SARS-CoV-2呈阳性，153例患者SARS-CoV-2呈阴性。SARS-CoV-2阳性患者的SBI发生率为16.4%，而SARS-CoV-2阴性患者的SBI发生率为47.1%。SARS-CoV-2阳性组中感染可疑的实验室参数显著低于SARS-CoV-2阴性组。在第二项比较中，对90例同时检测了SARS-CoV-2和其他呼吸道病毒的患者进行了评估。SARS-CoV-2阳性组的平均白细胞（WBC）、中性粒细胞绝对值（ANC）和C反应蛋白（CRP）水平显著低于其他呼吸道病毒阳性组，然而，SARS-CoV-2阳性和其他呼吸道病毒阳性患者组之间的平均淋巴细胞绝对值（ALC）、中性粒细胞与淋巴细胞比值（NLR）和降钙素原（PCT）水平以及SBI发生率没有显著差异。
这些结果表明，90日龄以下感染SARS-CoV-2的发热婴儿的SBI发生率低于未感染SARS-CoV-2的患者。这些数据与先前描述呼吸道病毒阳性发热婴儿SBI风险较低的研究一致。
不适用。
